Dr Reddy’s Laboratories Ltd has launched Docetaxel injection, a therapeutic equivalent of Taxotere, in the US market. The Hyderabad-based company had earlier obtained approval for the same from the US Food and Drug Administration.
It is indicated for the treatment of certain types of cancers. The brand and generic had sales of $218 million in the US for the most recent 12 months ending in September 2014, according to IMS Health, Dr Reddy’s said in a release.
Docetaxel injection is available in single dose, one vial formulation that does not require a prior dilution and is ready to add to the intravenous infusion solution.